Innovation in Urothelial cancer
Fundación HM Investigación
-
Dirección y Coordinación
Directora: Dra. Elena Sevillano Fernández. M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y Piel, HM Hospitales.
Coordinador: Dr. Jesús García-Donas. M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y Piel.
-
Ponentes (Speakers)
Dr. Joaquim Bellmunt
Dr. Pablo Gajate
Dr. Guillermo de Velasco
Dr. Alfonso Gómez de Liaño
Dr. Félix Guerrero -
Modalidad y Horario
Formato Híbrido (Presencial y online)
16:00 a 18:30 h (CET) -
Dirigido a
Profesionales sanitarios
Jueves 12 de noviembre de 2026
Innovation in Urothelial cancer
Precision Bladder Cancer: ctDNA, ADCs and the Future of Organ Preservation
16:00 – 16:10h Welcome and Introduction: From Radical Surgery to Molecular Personalization
• Why urothelial cancer is changing faster than ever.
• The transition from standard algorithms to precision.
16:10 – 16:40h SESSION I – NON-MUSCLE-INVASIVE DISEASE
BCG-Unresponsive Disease in 2026: Are We Replacing Cystectomy?
• IO + BCG combinations.
• TAR-200, CG0070, N-803 and novel intravesical platforms.
• How should we redefine BCG failure?
• Who should still undergo early cystectomy?
• Biomarkers for NMIBC decision-making.
16:40 – 17:25h SESSION II – MIBC & BLADDER-SPARING
The New Era of Bladder Preservation
• ctDNA-guided strategies.
• Defining true clinical complete response.
• Response-adapted treatment approaches.
• Can we safely omit cystectomy?
• Is ctDNA clearance a surrogate endpoint?
• Focused talks, expert debate and real-world cases.
17:25 – 18:00h SESSION III – ADVANCED UROTHELIAL CANCER
After EV-Pembrolizumab: What Comes Next?
• Sequencing ADCs after EV-P.
• FGFR3 inhibition in 2026.
• HER2-directed therapies.
• Mechanisms of resistance.
• Platinum-free strategies.
• Triplets and novel combinations.
• Real-world treatment algorithms.
18:00 – 18:30h FINAL PANEL & TAKE-HOME MESSAGES
What Will Change Clinical Practice in 2027?
• Will ctDNA become standard of care?
• Are ADCs replacing chemotherapy?
• Will bladder preservation become mainstream?
• Which biomarkers are truly ready for clinical implementation?
• Top practice-changing messages of 2026.
• Key unanswered questions.